14d
Gerresheimer AG (GRRMY) reports robust Q4 growth driven by biologics, despite challenges in full-year performance and market dynamics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback